FTRE
Fortrea Holdings Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 155.91K | $3.15M | n/a | n/a |
| Q2 2026 | 105 | +8 | 74.00M | $1.29B | +12 | −4 |
| Q1 2026 | 100 | -4 | 67.95M | $640.51M | +5 | −9 |
| Q4 2025 | 104 | 0 | 71.13M | $1.23B | +1 | −1 |
| Q3 2025 | 18 | 0 | 53.25M | $448.39M | +2 | −2 |
| Q2 2025 | 15 | +1 | 46.90M | $231.21M | +1 | n/a |
| Q1 2025 | 11 | -2 | 16.99M | $128.27M | +1 | −3 |
| Q4 2024 | 13 | +3 | 14.50M | $270.52M | +4 | −1 |
| Q3 2024 | 9 | -2 | 13.45M | $268.92M | n/a | −2 |
| Q2 2024 | 11 | n/a | 13.76M | $321.15M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 83.22K | -4.6% | $1.70M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 2 | Assenagon Asset Management S.A. | 72.69K | -79.0% | $1.45M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 327 holders, 98.96M shares, $906.93M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.15K sh · $53,061
Officer · 246 sh · $4,145
Officer · 4.89K sh · $88,985
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology